Summary

Glucagon-like peptide 1 agonists have been shown to improve glycemic control and reduce the risk of weight gain and hypoglycemia, but some patients have gastrointestinal (GI) side effects. Basal insulin offers glycemic control even while fasting and allows for individualized dosing but increases the risk of hypoglycemia and weight gain. This article discusses 1-year safety and efficacy data from the phase 3, open-label Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes [DUAL I].